Opportunities in somatostatin research: biological, chemical and therapeutic aspects (Q35600019)

9 August 2017

1 reference

title

Opportunities in somatostatin research: biological, chemical and therapeutic aspects. (English)

1 reference

9 August 2017

Gisbert Weckbecker

1

1 reference

9 August 2017

Ian Lewis

2

1 reference

9 August 2017

Rainer Albert

3

1 reference

9 August 2017

Herbert A Schmid

4

1 reference

9 August 2017

Daniel Hoyer

5

1 reference

9 August 2017

Christian Bruns

6

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Nature Reviews Drug Discovery

9 August 2017

published in

1 reference

9 August 2017

volume

2

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

999-1017

1 reference

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

9 August 2017

cites work

1 reference

31 March 2020

1 reference

Somatostatin (second of two parts).

31 March 2020

1 reference

Somatostatin analogs and radiopeptides in cancer therapy

31 March 2020

1 reference

High affinity binding sites for a somatostatin-28 analog in rat brain

31 March 2020

1 reference

A cortical neuropeptide with neuronal depressant and sleep-modulating properties

31 March 2020

1 reference

Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions

31 March 2020

1 reference

Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system

31 March 2020

1 reference

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney

31 March 2020

1 reference

Somatostatin analogs for diagnosis and treatment of cancer

31 March 2020

1 reference

Somatostatin: the neuroendocrine story

31 March 2020

1 reference

In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat

31 March 2020

1 reference

Inhibition of growth hormone release in humans by somatostatin

31 March 2020

1 reference

Solid phase synthesis of growth hormone-release inhibiting factor

31 March 2020

1 reference

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

31 March 2020

1 reference

31 March 2020

1 reference

Extended retro-inverso analogs of somatostatin

31 March 2020

1 reference

Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry

31 March 2020

1 reference

Recent advances in the development of nonpeptide somatostatin receptor ligands

31 March 2020

1 reference

SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs

31 March 2020

1 reference

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

31 March 2020

1 reference

A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.

31 March 2020

1 reference

Somatostatin and its receptor family

31 March 2020

1 reference

Receptor isoforms mediate opposing proliferative effects through gbetagamma-activated p38 or Akt pathways

31 March 2020

1 reference

Signal transduction of somatostatin in human B lymphoblasts

31 March 2020

1 reference

Drug design at peptide receptors: somatostatin receptor ligands

31 March 2020

1 reference

Molecular pharmacology of somatostatin-receptor subtypes.

31 March 2020

1 reference

Identification and characterization of a novel human cortistatin-like peptide

31 March 2020

1 reference

[125I]Tyr10-cortistatin14 labels all five somatostatin receptors

31 March 2020

1 reference

Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans

31 March 2020

1 reference

Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies

31 March 2020

1 reference

Binding properties of somatostatin receptor subtypes

31 March 2020

1 reference

Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene

31 March 2020

1 reference

Phospholipase C activation and Ca2+ mobilization by cloned human somatostatin receptor subtypes 1-5, in transfected COS-7 cells

31 March 2020

1 reference

Somatostatin receptor-mediated signaling in smooth muscle. Activation of phospholipase C-beta3 by Gbetagamma and inhibition of adenylyl cyclase by Galphai1 and Galphao

31 March 2020

1 reference

SSTR2 mediates the somatostatin-induced increase in intracellular Ca(2+) concentration and insulin secretion in the presence of arginine vasopressin in clonal beta-cell HIT-T15.

31 March 2020

1 reference

Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules

31 March 2020

1 reference

Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures

31 March 2020

1 reference

Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line

31 March 2020

1 reference

Inhibitory control of growth hormone secretion by somatostatin in rat pituitary GC cells: sst(2) but not sst(1) receptors are coupled to inhibition of single-cell intracellular free calcium concentrations

31 March 2020

1 reference

Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells

31 March 2020

1 reference

Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis

31 March 2020

1 reference

Intra-Islet Somatostatin Regulates Glucagon Release via Type 2 Somatostatin Receptors in Rats

31 March 2020

1 reference

Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels

31 March 2020

1 reference

Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion

31 March 2020

1 reference

Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin

31 March 2020

1 reference

Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes.

31 March 2020

1 reference

Neurotransmitter-induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin.

31 March 2020

1 reference

Somatostatin has an antiproliferative effect on concanavalin A-activated rat thymocytes

31 March 2020

1 reference

Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo

31 March 2020

1 reference

Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells

31 March 2020

1 reference

Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced apoptosis.

31 March 2020

1 reference

Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53.

31 March 2020

1 reference

New somatostatin analogs: will they fulfil old promises?

31 March 2020

1 reference

Internalization-defective mutants of somatostatin receptor subtype 2 exert normal signaling functions in hematopoietic cells

31 March 2020

1 reference

Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells

31 March 2020

1 reference

Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes

31 March 2020

1 reference

The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes.

31 March 2020

1 reference

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

31 March 2020

1 reference

Intracellular receptor for somatostatin in gastric mucosal cells: decomposition and reconstitution of somatostatin-stimulated phosphoprotein phosphatases

31 March 2020

1 reference

Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells

31 March 2020

1 reference

Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform: implication of JAK2.

31 March 2020

1 reference

Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.

31 March 2020

1 reference

Somatostatin inhibits thalamic network oscillations in vitro: actions on the GABAergic neurons of the reticular nucleus.

31 March 2020

1 reference

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

31 March 2020

1 reference

The pathophysiological consequences of somatostatin receptor internalization and resistance

31 March 2020

1 reference

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

31 March 2020

1 reference

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

31 March 2020

1 reference

Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment

31 March 2020

1 reference

In vivo internalization of the somatostatin sst2A receptor in rat brain: evidence for translocation of cell-surface receptors into the endosomal recycling pathway

31 March 2020

1 reference

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

31 March 2020

1 reference

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

31 March 2020

1 reference

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

31 March 2020

1 reference

G-protein-coupled receptor oligomerization and its potential for drug discovery

31 March 2020

1 reference

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

31 March 2020

1 reference

Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers

31 March 2020

1 reference

Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A).

31 March 2020

1 reference

Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization

31 March 2020

1 reference

Advances in understanding neuronal somatostatin receptors

31 March 2020

1 reference

Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin

31 March 2020

1 reference

A potent cyclic hexapeptide analogue of somatostatin

31 March 2020

1 reference

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

31 March 2020

1 reference

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors

31 March 2020

1 reference

Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1).

31 March 2020

1 reference

N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity

31 March 2020

1 reference

Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin

31 March 2020

1 reference

Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units

31 March 2020

1 reference

Peptide folding induces high and selective affinity of a linear and small beta-peptide to the human somatostatin receptor 4.

31 March 2020

1 reference

Beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors

31 March 2020

1 reference

Design and Synthesis of γ-Dipeptide Derivatives with Submicromolar Affinities for Human Somatostatin Receptors

31 March 2020

1 reference

Selective somatostatin sst(2) receptor blockade with the novel cyclic octapeptide, CYN-154806.

31 March 2020

1 reference

Highly potent cyclic disulfide antagonists of somatostatin

31 March 2020

1 reference

SST3-selective potent peptidic somatostatin receptor antagonists

31 March 2020

1 reference

Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity

31 March 2020

1 reference

Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia

31 March 2020

1 reference

Synthesis, conformational analysis and bioactivity of Lan-7, a lanthionine analog of TT-232

31 March 2020

1 reference

Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization

31 March 2020

1 reference

Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis

31 March 2020

1 reference

Effects of Heterocyclic Aromatic Substituents on Binding Affinities at Two Distinct Sites of Somatostatin Receptors. Correlation with the Electrostatic Potential of the Substituents

31 March 2020

1 reference

Optimization of a somatostatin mimetic via constrained amino acid and backbone incorporation

31 March 2020

1 reference

Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity

31 March 2020

1 reference

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.

31 March 2020

1 reference

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

31 March 2020

1 reference

Experience with indium-111 and yttrium-90-labeled somatostatin analogs

31 March 2020

1 reference

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

31 March 2020

1 reference

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

31 March 2020

1 reference

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

31 March 2020

1 reference

Preliminary experience on treatment of insulin-dependent diabetes mellitus with a long-acting somatostatin analogue (L363,586).

31 March 2020

1 reference

Effect of somatostatin on plasma glucose and insulin responses to glucagon and tolbutamide in man

31 March 2020

1 reference

Somatostatin does not Cause Sustained Fasting Hyperglycemia in Man

31 March 2020

1 reference

Prevention of the Dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog.

31 March 2020

1 reference

The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes

31 March 2020

1 reference

Somatostatin in peptic ulcer bleeding

31 March 2020

1 reference

Treatment of Acute Pancreatitis with Somatostatin: A Multicenter Double-Blind Trial

31 March 2020

1 reference

Cytoprotection-organoprotection by somatostatin: gastric and hepatic lesions

31 March 2020

1 reference

Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial

31 March 2020

1 reference

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

31 March 2020

1 reference

Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis

31 March 2020

1 reference

Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release

31 March 2020

1 reference

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

31 March 2020

1 reference

Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment

31 March 2020

1 reference

Medical treatment of functional pituitary tumors

31 March 2020

1 reference

Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors

31 March 2020

1 reference

Somatostatin analogs in acromegaly

31 March 2020

1 reference

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

31 March 2020

1 reference

Medical therapy of Cushing's disease

31 March 2020

1 reference

Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent

31 March 2020

1 reference

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

31 March 2020

1 reference

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

31 March 2020

1 reference

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

31 March 2020

1 reference

Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma

31 March 2020

1 reference

Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis

31 March 2020

1 reference

Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer.

31 March 2020

1 reference

Somatostatin analogue scintigraphy of malignant lymphomas

31 March 2020

1 reference

Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications

31 March 2020

1 reference

Somatostatin-receptor scintigraphy in primary breast cancer

31 March 2020

1 reference

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

31 March 2020

1 reference

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

31 March 2020

1 reference

Radiolabeled peptides in the diagnosis and therapy of oncological diseases

31 March 2020

1 reference

Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease

31 March 2020

1 reference

Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatosta

31 March 2020

1 reference

Somatostatin receptor scintigraphy using (99m)Tc-EDDA/HYNIC-TOC in graves' disease

31 March 2020

1 reference

Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease

31 March 2020

1 reference

Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization

31 March 2020

1 reference

Somatostatin analogues as drug therapies for retinopathies.

31 March 2020

1 reference

Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future?

31 March 2020

1 reference

Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study.

31 March 2020

1 reference

Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro

31 March 2020

1 reference

Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy

31 March 2020

1 reference

Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease

31 March 2020

1 reference

Octreotide and diabetes: theoretical and experimental aspects

31 March 2020

1 reference

Effect of octreotide on experimental diabetic renal and glomerular growth: importance of early intervention

31 March 2020

1 reference

Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice

31 March 2020

1 reference

Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats

31 March 2020

1 reference

Regional Brain Concentrations of Neuropeptides in Huntington's Chorea and Schizophrenia

31 March 2020

1 reference

Somatostatin and epilepsy.

31 March 2020

1 reference

Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis.

31 March 2020

1 reference

Effects of octreotide on responses to colorectal distension in the rat

31 March 2020

1 reference

Identification of somatostatin sst2(a) receptor expressing neurones in central regions involved in nociception

31 March 2020

1 reference

Inhibition of coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide

31 March 2020

1 reference

The somatostatin analog octreotide as potential treatment for re-stenosis and chronic rejection

31 March 2020

1 reference

Somatostatin receptors and the potential use of Sandostatin to interfere with vascular remodelling

31 March 2020

1 reference

Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis

31 March 2020

1 reference

Effect of endothelial and adventitial injury on somatostatin receptor expression

31 March 2020

1 reference

Growing vascular endothelial cells express somatostatin subtype 2 receptors

31 March 2020

1 reference

Current experience with somatostatin analogues, especially angiopeptine, for the prevention of transplant vasculopathy in heart transplantation

31 March 2020

1 reference

Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty.

31 March 2020

1 reference

Somatostatin in inflammatory bowel disease

31 March 2020

1 reference

Peptides as regulators of the immune system: emphasis on somatostatin

31 March 2020

1 reference

Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation

31 March 2020

1 reference

Somatostatin receptors on circulating human blood cells

31 March 2020

1 reference

SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release

31 March 2020

1 reference

Modulation of cytokine production in activated human monocytes by somatostatin

31 March 2020

1 reference

Somatostatin analogues suppress the inflammatory reaction in vivo

31 March 2020

1 reference

Octreotide effectively decreases mucosal damage in experimental colitis

31 March 2020

1 reference

Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin

31 March 2020

1 reference

Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806.

31 March 2020

1 reference

Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2

31 March 2020

1 reference

Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists

31 March 2020

1 reference

Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1255

1 reference

9 August 2017

1 reference